Biogen is a global biotechnology company dedicated to discovering, developing, and delivering innovative therapies for neurological and neurodegenerative diseases
The company focuses on addressing serious conditions such as multiple sclerosis, Alzheimer's disease, and spinal muscular atrophy, among others. Through advanced research and development, Biogen aims to create breakthrough treatments that improve the lives of patients and their families, and it leverages its expertise in biologics and immunology to bring novel solutions to market. Additionally, Biogen is committed to advancing science and fostering collaboration within the medical and scientific communities to further enhance patient care.
Shareholders of Biogen would probably like to forget the past six months even happened. The stock dropped 31.4% and now trades at $140.49. This was partly driven by its softer quarterly results and might have investors contemplating their next move.
Multiple sclerosis patients report severe side effects, including relapses and mobility issues, after switching from Tysabri to Tyruko in an NHS cost-saving move. Regulators and experts are assessing the impact.
Biogen shares have fallen over 70% from its highs nearly 12-years ago, but value investors should take a look at its metrics of just 12.4 P/E and P/B of 1.2X
Biogen and Stoke partner on zorevunersen for Dravet syndrome, with a Phase 3 trial starting in 2025. Stoke gets $165 million upfront and milestone payments.
Biogen Inc. (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK) today announced a collaboration for the development and commercialization of zorevunersen, a potential first-in-class disease modifying medicine in development for the treatment of Dravet syndrome, in all territories outside the United States, Canada, and Mexico. Zorevunersen is an investigational antisense oligonucleotide (ASO) that targets the SCN1A gene, the underlying cause of most cases of Dravet syndrome. Stoke recently announced plans to initiate a global Phase 3 registrational study of zorevunersen (EMPEROR) following successful alignment with regulatory agencies in the United States, Europe, and Japan. The study is on track to initiate in the second quarter of 2025, with a pivotal data readout expected in the second half of 2027, which is anticipated to support global regulatory filings.
Stoke retains exclusive rights for zorevunersen in the United States, Canada, and Mexico; Biogen receives exclusive rest of world commercialization rights
Biogen's Q4 EPS and revenue topped estimates, but analysts cite Medicare changes and MS declines as headwinds. Leqembi and Skyclarys remain key growth drivers.
Biotech company Biogen (NASDAQBIIB) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up 2.9% year on year to $2.45 billion. Its non-GAAP profit of $3.44 per share was 2.3% above analysts’ consensus estimates.
Biogen beat Q4 estimates with a 17% EPS rise and $2.46 billion in sales. The company expects revenue declines in 2025 as multiple sclerosis drug sales drop.
A hotter-than-expected inflation report initially rattled markets on Wednesday morning, but investors found confidence to buy the dip, helping major indexes recover most losses by midday trading in New York.
Biogen posted strong Q4 results, surpassing estimates, while forecasting a 2025 revenue decline. The company secured up to $250 million in R&D funding from Royalty Pharma.
